Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Short and long term, in vitro and in vivo correlations of cellular and tissue responses to mesoporous silicon nanovectors.

Martinez JO, Boada C, Yazdi IK, Evangelopoulos M, Brown BS, Liu X, Ferrari M, Tasciotti E.

Small. 2013 May 27;9(9-10):1722-33. doi: 10.1002/smll.201201939. Epub 2012 Dec 16.

2.

Mitotic trafficking of silicon microparticles.

Serda RE, Ferrati S, Godin B, Tasciotti E, Liu X, Ferrari M.

Nanoscale. 2009 Nov;1(2):250-9. doi: 10.1039/b9nr00138g. Epub 2009 Oct 5.

3.

PLGA-Mesoporous Silicon Microspheres for the in Vivo Controlled Temporospatial Delivery of Proteins.

Minardi S, Pandolfi L, Taraballi F, De Rosa E, Yazdi IK, Liu X, Ferrari M, Tasciotti E.

ACS Appl Mater Interfaces. 2015 Aug 5;7(30):16364-73. doi: 10.1021/acsami.5b03464. Epub 2015 Jul 23.

PMID:
26108253
4.

Degradation and biocompatibility of multistage nanovectors in physiological systems.

Martinez JO, Evangelopoulos M, Chiappini C, Liu X, Ferrari M, Tasciotti E.

J Biomed Mater Res A. 2014 Oct;102(10):3540-9. doi: 10.1002/jbm.a.35017. Epub 2013 Nov 16.

5.

Multi-stage delivery nano-particle systems for therapeutic applications.

Serda RE, Godin B, Blanco E, Chiappini C, Ferrari M.

Biochim Biophys Acta. 2011 Mar;1810(3):317-29. doi: 10.1016/j.bbagen.2010.05.004. Epub 2010 May 21. Review.

6.

Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics.

Godin B, Tasciotti E, Liu X, Serda RE, Ferrari M.

Acc Chem Res. 2011 Oct 18;44(10):979-89. doi: 10.1021/ar200077p. Epub 2011 Sep 8. Review.

7.

Applications of zero-valent silicon nanostructures in biomedicine.

Kafshgari MH, Voelcker NH, Harding FJ.

Nanomedicine (Lond). 2015;10(16):2553-71. doi: 10.2217/nnm.15.91. Epub 2015 Aug 21. Review.

PMID:
26295171
8.

Shape matters when engineering mesoporous silica-based nanomedicines.

Hao N, Li L, Tang F.

Biomater Sci. 2016 Apr;4(4):575-91. doi: 10.1039/c5bm00589b. Epub 2016 Jan 28.

PMID:
26818852
9.

Silicon nanomaterials platform for bioimaging, biosensing, and cancer therapy.

Peng F, Su Y, Zhong Y, Fan C, Lee ST, He Y.

Acc Chem Res. 2014 Feb 18;47(2):612-23. doi: 10.1021/ar400221g. Epub 2014 Jan 7. Review.

PMID:
24397270
10.

Drug delivery/imaging multifunctionality of mesoporous silica-based composite nanostructures.

Chen Y, Chen H, Shi J.

Expert Opin Drug Deliv. 2014 Jun;11(6):917-30. doi: 10.1517/17425247.2014.908181. Epub 2014 Apr 19. Review.

PMID:
24746014
11.

Metabolism of nanomaterials in vivo: blood circulation and organ clearance.

Wang B, He X, Zhang Z, Zhao Y, Feng W.

Acc Chem Res. 2013 Mar 19;46(3):761-9. doi: 10.1021/ar2003336. Epub 2012 Jun 21.

PMID:
23964655
12.

Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats.

Bimbo LM, Sarparanta M, Santos HA, Airaksinen AJ, Mäkilä E, Laaksonen T, Peltonen L, Lehto VP, Hirvonen J, Salonen J.

ACS Nano. 2010 Jun 22;4(6):3023-32. doi: 10.1021/nn901657w.

PMID:
20509673
13.

Nanostructured porous Si-based nanoparticles for targeted drug delivery.

Shahbazi MA, Herranz B, Santos HA.

Biomatter. 2012 Oct-Dec;2(4):296-312. doi: 10.4161/biom.22347. Review.

14.

Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.

Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G.

Clin Cancer Res. 2013 Apr 1;19(7):1806-15. doi: 10.1158/1078-0432.CCR-12-2764. Epub 2013 Feb 5.

15.

Systematic in vitro and in vivo study on porous silicon to improve the oral bioavailability of celecoxib.

Riikonen J, Correia A, Kovalainen M, Näkki S, Lehtonen M, Leppänen J, Rantanen J, Xu W, Araújo F, Hirvonen J, Järvinen K, Santos HA, Lehto VP.

Biomaterials. 2015 Jun;52:44-55. doi: 10.1016/j.biomaterials.2015.02.014. Epub 2015 Feb 21.

PMID:
25818412
16.

Multifunctional upconversion mesoporous silica nanostructures for dual modal imaging and in vivo drug delivery.

Li C, Yang D, Ma P, Chen Y, Wu Y, Hou Z, Dai Y, Zhao J, Sui C, Lin J.

Small. 2013 Dec 20;9(24):4150-9. doi: 10.1002/smll.201301093. Epub 2013 Jul 11.

PMID:
23843254
17.

The role of nanostructured mesoporous silicon in discriminating in vitro calcification for electrospun composite tissue engineering scaffolds.

Fan D, Akkaraju GR, Couch EF, Canham LT, Coffer JL.

Nanoscale. 2011 Feb;3(2):354-61. doi: 10.1039/c0nr00550a. Epub 2010 Nov 25.

PMID:
21107480
18.

Evaluation of cell function upon nanovector internalization.

Martinez JO, Parodi A, Liu X, Kolonin MG, Ferrari M, Tasciotti E.

Small. 2013 May 27;9(9-10):1696-702. doi: 10.1002/smll.201202001. Epub 2012 Nov 20.

19.

Acute toxicity and in vivo biodistribution of monodispersed mesoporous bioactive glass spheres in intravenously exposed mice.

Mao C, Chen X, Hu Q, Miao G, Lin C.

Mater Sci Eng C Mater Biol Appl. 2016 Jan 1;58:682-91. doi: 10.1016/j.msec.2015.09.002. Epub 2015 Sep 8.

PMID:
26478360
20.

Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole.

Kinnari P, Mäkilä E, Heikkilä T, Salonen J, Hirvonen J, Santos HA.

Int J Pharm. 2011 Jul 29;414(1-2):148-56. doi: 10.1016/j.ijpharm.2011.05.021. Epub 2011 May 12.

PMID:
21601623

Supplemental Content

Support Center